

Queensland Health

Treatment of tuberculosis in renal disease in adults

Guideline, Version 5.0 May 2023



Queensland
Government

Treatment of tuberculosis in renal disease in adults - Guideline, Version 5.0 May 2023

Published by the State of Queensland (Queensland Health), May 2023

This document is licensed under a Creative Commons Attribution 3.0 Australia licence.



To view a copy of this licence, visit creativecommons.org/licenses/by/3.0/au

© State of Queensland (Queensland Health) 2023

You are free to copy, communicate and adapt the work, as long as you attribute the State of Queensland (Queensland Health).

For more information contact:

Communicable Diseases Branch, Queensland Health, GPO Box 48, Brisbane QLD 4001,
email CDIM_Infection_Management@health.qld.gov.au

An electronic version of this document is available at <https://www.health.qld.gov.au/clinical-practice/guidelines-procedures/diseases-infection/diseases/tuberculosis/guidance/guidelines>

Please note: Updates after May are amended in the online version of Treatment of tuberculosis in renal disease ONLY – printed copies may not be current

Contents

1	General considerations	4
2	Recommendations	5
	References	13
	Approval and implementation	15
	Version Control	15

Key critical points

- Renal failure is a risk factor for developing tuberculosis (TB).
- Diminished renal clearance of drugs used to treat TB puts the patient at increased risk of toxicity.
- Careful calculation of dose and frequency is required to maximise pharmacokinetic/pharmacodynamic (PkPD) targets and minimise the risk of toxicity coupled with clinical and laboratory monitoring for adverse effects.
- Of the most commonly used agents to treat TB (the first line agents of rifampicin, isoniazid, ethambutol and pyrazinamide) only ethambutol is predominately eliminated renally and drug accumulation in the presence of renal disease can lead to irreversible ocular toxicity.
- Co-existent disease and administration of other medications may have important consequences for the risk of adverse effects and drug-drug interactions.

1 General considerations

Renal failure is a risk factor for developing tuberculosis (TB). Extra-pulmonary TB is more common in patients with chronic renal disease when compared to those with normal renal function. Peritoneal disease is especially frequent in patients on chronic ambulatory peritoneal dialysis (CAPD).

There are no randomised controlled trials that provide evidence to guide TB treatment in renal failure. Current treatment guidelines are based on reports from case series, the known pharmacological characteristics of the drugs used, and recommendations of experts in the area, including international agencies involved in TB control.

The following factors will influence the treatment of a patient with chronic kidney disease and TB:

- drug pharmacokinetics, including the proportion of drug excreted by the kidneys and its clearance by dialysis (both haemodialysis and peritoneal dialysis), which affects the serum levels of drugs and consequently, the toxicity
- the severity of anticipated toxicity with raised blood levels of drugs and the availability of alternate effective agents to cure the patient of TB
- co-existent illnesses and possible drug interactions which may affect therapy.

2 Recommendations

1. Where there is significant renal impairment, standard 6 or 9-month regimens are generally used but ethambutol is withheld for:
 - a. drug-susceptible or bacteriologically-negative disease
 - b. where susceptibilities are not yet available, but drug resistance is not suspected.
2. Prolongation of treatment is an individual decision based on specific clinical circumstances and may occur in cases with immunosuppression or extensive disease. In general, standard dosages are used and, where indicated, a reduction in dosing frequency is preferred to lower dosage so as not to compromise the regimen with sub-therapeutic drug levels.
3. Drug-resistant disease is treated with appropriate drugs as indicated by susceptibility testing, detailed according to guidelines.
4. Haemodialysis (HD) often leads to the elimination of most TB drugs and medications are usually given after dialysis. There is a paucity of data regarding the elimination of drugs in CAPD.
5. Careful monitoring of patients is essential as side effects (mainly neuropsychiatric problems, hepatitis and optic neuropathy) are noted to occur at higher levels in patients with renal failure and especially those on dialysis.
6. Therapeutic drug monitoring is advocated with aminoglycosides. Monitoring of some other TB drugs is available in Queensland but should only be considered in complex cases with advanced renal disease in consultation with a consultant physician experienced in treating TB.
7. The treatment of TB in patients with mild renal impairment, and with glomerular filtration rate (GFR) between 30 to 60mL/min, should be individualised using standard drugs in dose ranges in the lower range of usual recommendations for patients with normal renal function, with careful monitoring of side effects.
8. Ethambutol is used to prevent the emergence of rifampicin resistance with isoniazid-resistant isolates. In Australia, isoniazid resistance occurs in 7 to 10 per cent of isolates, predominantly in overseas-born patients. In these situations, where ethambutol use is considered essential (until full drug susceptibility test results are available), refer to the table for dosing recommendations.
9. All but first-line drugs must only be used after discussion with a consultant physician experienced in treating TB and in consultation with a renal physician.
10. International guidelines demonstrate small variations in recommended doses and variations in the categorisation of Cr Cl ranges. Some agents used for drug-resistant TB may not be well studied and contemporary literature should be checked prior to the prescription of a second-line agent. For example at the time of writing of this guideline, there was no recommendation published on the use of pretomanid or delamanid in renal disease.

Guide to use of individual agents in renal failure

Antimycobacterial agent and normal dose	Dosage adjustment according to established degree of renal function					Comments and recommendations
	Established creatinine clearance (CrCL)			Intermittent haemodialysis (IHD)	Peritoneal dialysis (PD)	
	30–60 mL/min	10–29 mL/min	<10 mL/min			
Rifampicin 10mg/kg/day up to 600mg	No dose adjustment required	No dose adjustment required	No dose adjustment required	No dose adjustment required	No dose adjustment required	<ul style="list-style-type: none"> • Can be used safely in renal disease. • Main route of clearance is hepatobiliary. • Exercise caution with concomitant drugs due to the potential for significant drug-drug interactions, e.g. renal transplant patients on Tacrolimus or Cyclosporin.
Isoniazid 5mg/kg/day up to 300mg	No dose adjustment required	No dose adjustment required	No dose adjustment required	No dose adjustment required	No dose adjustment required	<ul style="list-style-type: none"> • Can be used in renal disease. • Main route of clearance is hepatic. • Increased risk of neurotoxicity in patients with renal disease and supplemental pyridoxine (25mg/day) should be co-prescribed.

Antimycobacterial agent and normal dose	Dosage adjustment according to established degree of renal function					Comments and recommendations
	Established creatinine clearance (CrCL)			Intermittent haemodialysis (IHD)	Peritoneal dialysis (PD)	
	30–60 mL/min	10–29 mL/min	<10 mL/min			
Pyrazinamide 25mg/kg/day	No dose adjustment required	25-30 mg/kg q48h	25-30 mg/kg 3 times/week	25-30mg/kg 3 times/week after dialysis sessions	No dose adjustment required	<ul style="list-style-type: none"> • Can be used safely in renal disease. • Main route of clearance is hepatic with active metabolites undergoing some renal clearance. • Monitor LFTs for hepatotoxicity. • Monitor uric acid levels.
Ethambutol 15mg/kg/day	No dose adjustment required	15mg/kg q48h	15mg/kg q48h	15mg/kg 3 time/week after dialysis sessions	15mg/kg q48h	<ul style="list-style-type: none"> • AVOID use unless essential in renal disease with CrCl <30mL/min. • Main route of clearance is renal. • Ocular toxicity is a significant concern in patients with renal disease and regular ophthalmological reviews are essential. • TDM can be considered to reduce the risk of toxicity.
Levofloxacin 750-1000mg daily	750-1000mg q48hrs (Sandford)	750-1000mg 3 times/week	750-1000mg 3 times/week	750-1000mg 3 times/week	Consult with a renal physician	<ul style="list-style-type: none"> • Unlike moxifloxacin, levofloxacin is significantly eliminated by the kidneys; moxifloxacin may be preferred in significant renal impairment.

Antimycobacterial agent and normal dose	Dosage adjustment according to established degree of renal function					Comments and recommendations
	Established creatinine clearance (CrCL)			Intermittent haemodialysis (IHD)	Peritoneal dialysis (PD)	
	30–60 mL/min	10–29 mL/min	<10 mL/min			
Moxifloxacin 400mg/day	No dose adjustment required	No dose adjustment required	No dose adjustment required	No dose adjustment required	No dose adjustment required	<ul style="list-style-type: none"> • Can be used with caution in renal disease. • Main route of clearance is hepatobiliary with some renal clearance. • Higher risk of adverse effects in patients with renal disease including neurotoxicity and tendinopathies. Concomitant corticosteroid use further increases risk. • Co-administration with antacids, phosphate binders or supplements containing calcium, iron, magnesium, or aluminium must be avoided due to markedly reduced absorption of fluoroquinolones. Dose at bedtime, or 2 hours before or after other medications, to achieve separation.
Bedaquiline 400mg daily for 2 weeks; 200mg thrice weekly thereafter	No dose adjustment required	Use with caution and consider TDM	<ul style="list-style-type: none"> • Bedaquiline has a long half-life (5.5 months) and is predominantly excreted in faeces with minimal renal excretion. • No dose adjustment is recommended for mild to moderate renal impairment, but caution is recommended in more severe renal failure. 			

Antimycobacterial agent and normal dose	Dosage adjustment according to established degree of renal function					Comments and recommendations
	Established creatinine clearance (CrCL)			Intermittent haemodialysis (IHD)	Peritoneal dialysis (PD)	
	30–60 mL/min	10–29 mL/min	<10 mL/min			
Clofazimine 100 mg daily	No dose adjustment required	No dose adjustment required	No dose adjustment required	No dose adjustment required	No dose adjustment required	<ul style="list-style-type: none"> Can be used safely in renal disease.
Linezolid 600mg/day	No dose adjustment required	No dose adjustment required	No dose adjustment required	No dose adjustment required	No dose adjustment required	<ul style="list-style-type: none"> Can be used with caution in renal disease. Main route of clearance is hepatic with some renal clearance. Increased risk of haematological toxicity and peripheral neuropathy in patients with renal disease. TDM can be considered to optimize dosing and minimize risk of toxicity.
Streptomycin 15mg/kg/day	15mg/kg individual doses with interval between doses adjusted to achieve undetectable plasma trough levels.					Aminoglycosides & Capreomycin <ul style="list-style-type: none"> Can be used with significant caution in renal disease. Main route of clearance is renal. Dose adjustment and therapeutic drug monitoring are required due to toxicity risk and changes in drug clearance over time. Dosing intervals should be extended to allow for clearance of drug between doses. Intervals should be extended to achieve an undetectable plasma trough level prior to each dose.
Amikacin 15mg/kg/day	15mg/kg individual doses with interval between doses adjusted to achieve undetectable plasma trough levels.					
Capreomycin 15mg/kg/day	Capreomycin is no longer recommended for treatment of drug-resistant tuberculosis.					

Antimycobacterial agent and normal dose	Dosage adjustment according to established degree of renal function					Comments and recommendations
	Established creatinine clearance (CrCL)			Intermittent haemodialysis (IHD)	Peritoneal dialysis (PD)	
	30–60 mL/min	10–29 mL/min	<10 mL/min			
Capreomycin 15mg/kg/day	Capreomycin is no longer recommended for treatment of drug-resistant tuberculosis.					<ul style="list-style-type: none"> For haemodialysis patients, doses can be administered intravenously at the end of the dialysis session, but dosing may not be required for each session. Monitoring should include regular U&Es to assess renal function along with clinical assessment, audiometry +/- dynamic visual acuity testing (where feasible) to assess oto/ vestibulotoxicity.
Prothionamide 15–20mg/kg/day in divided doses	No dose adjustment required	No dose adjustment required	250mg q12h	250mg q12h	250mg q12h	<ul style="list-style-type: none"> Can be used in renal disease. Main route of clearance is hepatic. Monitor for neuropathy and hepatotoxicity.
Cycloserine 10–15mg/kg/day in divided doses (typically 500–750mg for Australian TB patients >50kg)	250mg q12h	250mg q24h	250mg Q24h	250mg q24h or 500mg 3 times per week (BTS) (given after dialysis on those days)	500mg q48h or 3 times per week (BTS) or longer (VIDS)	<ul style="list-style-type: none"> AVOID if possible in renal disease. Main route of clearance is renal. Increased risk of significant neurotoxicity in patients with renal disease. Plasma level monitoring recommended but currently unavailable in Queensland. Recommended range 20-35mg/L (ATS)

Antimycobacterial agent and normal dose	Dosage adjustment according to established degree of renal function					Comments and recommendations
	Established creatinine clearance (CrCL)			Intermittent haemodialysis (IHD)	Peritoneal dialysis (PD)	
	30–60 mL/min	10–29 mL/min	<10 mL/min			
Para-aminosalicylic Acid (PAS) 8–12g/day in divided doses	No dose adjustment required	4g q12h	4g q12h	4g q12h	4g q12h	<ul style="list-style-type: none"> • Use with significant caution in renal disease. • Main route of clearance is renal. • Increased risk of acidosis and gastrointestinal side effects.
Delamanid 100mg twice daily	No dose adjustment required with CrCl > 50mL/min	There are no safety or efficacy data on use in patients with severe renal impairment or renal replacement therapy. Use is not currently recommended				<ul style="list-style-type: none"> • Main route of clearance of active drug is extrarenal. • Pharmacokinetics of metabolites associated with toxicity are not well understood currently.
Pretomanid 200mg daily	There are no safety or efficacy data on use in patients with renal impairment or receiving renal replacement therapy. Use is not currently recommended.					<ul style="list-style-type: none"> • Main route of clearance of active drug is extrarenal however the pharmacokinetics of metabolites are not well understood currently.

* When daily doses are due on haemodialysis days, it is advisable to administer drugs after the dialysis session – afternoon or evening – to minimise the removal of the active drug by dialysis.

References

- American Thoracic Society; CDC; Infectious Diseases Society of America. (2003). Treatment of tuberculosis. *Morbidity and Mortality Weekly Recommendations and Reports*. 52(RR-11):1-77.
- Partners in Health. (2009). Medical management of Multidrug-resistant tuberculosis. www.pih.org
- European Respiratory Society (1999). Tuberculosis Management in Europe. *European Respiratory Journal*, 14: 978-992.
- Bureau of Tuberculosis Control New York City. (1999). *Clinical Policies and Protocols* www.ci.nyc.ny.us/health
- New York City Department of Health and Mental Hygiene.(2022) Bureau of Tuberculosis Control Clinical Policies and Program Manual 5th edition www.ci.nyc.ny.us/health
- Ross, J, D., Horne, N.W. (1983). *Modern drug treatment in Tuberculosis*. The Chest, Heart and Stroke Association (6th ed.).
- Bennett, W, M. (1988). Guide to drug dosage in renal failure. *Clinical Pharmacokinetics*, 15:326-54.
- Girling, G.J. (1982). Adverse effects of anti-tuberculosis drugs. *Current Therapeutics* 9, 101-116.
- Launay-Vacher, V., Izzedine, H., Deray, G. (2005). Pharmacokinetic considerations in the treatment of Tuberculosis in patients with renal failure. *Clinical Pharmacokinetics* 44 (3), 221-235.
- Malone, R.S., Fish, D.N., Spiegel, D.M., et al. (1999). The effect of hemodialysis on isoniazid, rifampicin, pyrazinamide, and ethambutol. *American Journal of Respiratory Critical Care Medicine*, 159, 1580-1584.
- Douglas, J.G., Mcleod, M.J. (1999). Pharmacokinetic factors in the modern drug treatment of tuberculosis. *Clinical Pharmacokinetics* 37,127-46.
- Quantrill, S.J., Woodhead, M.A., Bell, C.E. et al. (2002). Side effects of antituberculosis drug treatment in patients with chronic renal failure. *European Respiratory Journal*, 20 (2), 440-443.
- Gabardi, S., Abramson, S. (2005). Drug dosing in chronic kidney disease. *Medical Clinics of North America* 89: 649-687.
- Ellard GA. (1993). Chemotherapy of tuberculosis for patients with renal impairment. *Nephron*, 64 (2), 169-181.
- Varughese, A., Brater, D.C., Benet, L.Z et al. (1986). Ethambutol kinetics in patients with impaired renal function. *American Review of Respiratory Disease*, 134, 34-38.
- British Thoracic Society Standards of Care Committee and Joint Tuberculosis Committee, Milburn, H., Ashman, N., Davies, P., Doffman, S., Drobniewski, F., Khoo, S., Ormerod, P., Ostermann, M., Snelson, C. (2010). Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease. *Thorax*, 65 (6), 557-570.

Antibiotic Expert Group (2019) Therapeutic guidelines: antibiotic. Version 16. Melbourne.

The Sanford Guide to antimicrobial therapy 50th ed. (2020) Antimicrobial Therapy, Incorporated.

Curry International Tuberculosis Center and California Department of Public Health, (2016) *Drug-Resistant Tuberculosis: A Survival Guide for Clinicians, Third Edition*

Approval and implementation

Policy Custodian	Policy Contact Details	Approval Date	Approver
<i>Executive Director-Communicable Diseases Branch</i>	<i>Heidi.carroll2@health.qld.gov.au</i>	<i>[date]</i>	<i>Dr Heidi Carroll</i>
<i>Tuberculosis Expert Advisory Group</i>	<i>ndpc@health.qld.gov.au</i>	<i>19 May 2023</i>	<i>Tuberculosis Expert Advisory Group</i>

Version Control

Version	Date	Date of next revision	Comments
1.0	March 2007		<i>Rescinded</i>
2.0	April 2013	April 2015	
3.0	February 2015	February 2017	
4.0	August 2021	August 2022	
5.0	May 2023	May 2025	<i>Minor updates and inclusion of medicines in new WHO endorsed regimes</i>